R. Marcus

501 total citations
26 papers, 387 citations indexed

About

R. Marcus is a scholar working on Psychiatry and Mental health, Clinical Psychology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, R. Marcus has authored 26 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Psychiatry and Mental health, 7 papers in Clinical Psychology and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in R. Marcus's work include Schizophrenia research and treatment (15 papers), Bipolar Disorder and Treatment (9 papers) and Child and Adolescent Psychosocial and Emotional Development (5 papers). R. Marcus is often cited by papers focused on Schizophrenia research and treatment (15 papers), Bipolar Disorder and Treatment (9 papers) and Child and Adolescent Psychosocial and Emotional Development (5 papers). R. Marcus collaborates with scholars based in Germany, United States and Sweden. R. Marcus's co-authors include Robert D. McQuade, William H. Carson, Robert L. Findling, Robert A. Forbes, Svetlana А. Ivanova, Adelaide S. Robb, Na Jin, Taro Iwamoto, Margaretta Nyilas and Д. Арчибалд and has published in prestigious journals such as American Journal of Psychiatry, Schizophrenia Research and The Journal of Clinical Psychiatry.

In The Last Decade

R. Marcus

25 papers receiving 364 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Marcus Germany 9 334 99 81 52 40 26 387
R.N. Marcus United States 5 396 1.2× 59 0.6× 43 0.5× 71 1.4× 48 1.2× 10 449
Baerbel Allingham United States 7 307 0.9× 55 0.6× 57 0.7× 27 0.5× 46 1.1× 10 365
Na Jin United States 10 636 1.9× 169 1.7× 151 1.9× 57 1.1× 79 2.0× 17 738
Sheila Assunção-Talbott United States 8 308 0.9× 72 0.7× 33 0.4× 57 1.1× 44 1.1× 9 367
Angela Hill United States 10 235 0.7× 113 1.1× 29 0.4× 50 1.0× 38 0.9× 21 422
Philippe Bouhours France 11 329 1.0× 70 0.7× 46 0.6× 131 2.5× 88 2.2× 20 481
Mary Mackle United States 13 444 1.3× 61 0.6× 53 0.7× 74 1.4× 26 0.7× 22 463
Koen P. Grootens Netherlands 13 249 0.7× 123 1.2× 29 0.4× 28 0.5× 41 1.0× 37 460
W. Chrzanowski Poland 7 413 1.2× 96 1.0× 46 0.6× 126 2.4× 110 2.8× 11 497
Minna Torniainen Finland 7 356 1.1× 88 0.9× 20 0.2× 54 1.0× 63 1.6× 14 476

Countries citing papers authored by R. Marcus

Since Specialization
Citations

This map shows the geographic impact of R. Marcus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Marcus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Marcus more than expected).

Fields of papers citing papers by R. Marcus

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Marcus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Marcus. The network helps show where R. Marcus may publish in the future.

Co-authorship network of co-authors of R. Marcus

This figure shows the co-authorship network connecting the top 25 collaborators of R. Marcus. A scholar is included among the top collaborators of R. Marcus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Marcus. R. Marcus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marcus, R., et al.. (2024). Long-term Safety of KarXT (Xanomeline and Trospium) in Schizophrenia. Neuroscience Applied. 3. 104222–104222. 1 indexed citations
2.
Kinon, Bruce J., Stefan Leucht, Carol A. Tamminga, et al.. (2024). Rationale for Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia. The Journal of Clinical Psychiatry. 85(3). 6 indexed citations
3.
4.
5.
Youngstrom, Eric A., Joan Zhao, Raymond Mankoski, et al.. (2013). Clinical Significance of Treatment Effects with Aripiprazole versus Placebo in a Study of Manic or Mixed Episodes Associated with Pediatric Bipolar I Disorder. Journal of Child and Adolescent Psychopharmacology. 23(2). 72–79. 21 indexed citations
6.
Findling, Robert L., Adelaide S. Robb, Margaretta Nyilas, et al.. (2008). A Multiple-Center, Randomized, Double-Blind, Placebo-Controlled Study of Oral Aripiprazole for Treatment of Adolescents With Schizophrenia. American Journal of Psychiatry. 165(11). 1432–1441. 194 indexed citations
7.
Ebrecht, M, M Kungel, Christian Werner, et al.. (2007). Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. Pharmacopsychiatry. 40(5). 38 indexed citations
8.
Findling, Robert L., J Blumer, Ralph E. Kauffman, et al.. (2004). Pharmacokinetic effects of aripiprazole in children and adolescents with conduct disorder. The International Journal of Neuropsychopharmacology. 7. 10 indexed citations
9.
Stock, Elyse, Д. Арчибалд, Stavros Tourkodimitris, et al.. (2004). P.2.067 Long-term effects of aripiprazole on affective symptoms of schizophrenia. European Neuropsychopharmacology. 14. S261–S261. 9 indexed citations
10.
Grunze, Heinz, William H. Carson, R. Marcus, et al.. (2004). P.2.072 Aripiprazole treatment for acute mania in patients with bipolar I disorder: A placebo-controlled study. European Neuropsychopharmacology. 14. S264–S264. 1 indexed citations
11.
Kungel, M, et al.. (2004). Efficacy and tolerability of aripiprazole compared to perphenazine in treatment-resistant schizophrenia. Pharmacopsychiatry. 36(5). 1 indexed citations
12.
Carson, William H., et al.. (2003). Safety and tolerability of aripiprazole in patients with schizophrenia stratified by race. Schizophrenia Research. 60(1). 291–291. 2 indexed citations
13.
Carson, William H., et al.. (2003). Meta-analysis of the efficacy of aripiprazole in schizophrenia. Schizophrenia Research. 60(1). 276–276. 3 indexed citations
14.
McQuade, Robert D., D. Jody, John M. Kane, et al.. (2003). P.2.105 Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia. European Neuropsychopharmacology. 13. S326–S326. 7 indexed citations
15.
Kostić, Dušan, George Manos, Elyse Stock, et al.. (2003). P.2.111 Long-term effects of aripirazole on the negative symptoms of schizophrenia. European Neuropsychopharmacology. 13. S328–S328. 7 indexed citations
16.
Casey, Dympna, R. Marcus, William H. Carson, et al.. (2003). Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. Schizophrenia Research. 60(1). 276–276. 7 indexed citations
17.
Findling, Robert L., Jeffrey L. Blumer, James R. Batterson, et al.. (2003). P.2.127 Aripiprazole in pediatric-conduct disorder: A pilot study. European Neuropsychopharmacology. 13. S335–S335. 19 indexed citations
18.
Bourin, Michel, et al.. (2003). P.2.121 Aripiprazole vs. haloperidol for maintained treatment effect in acute mania. European Neuropsychopharmacology. 13. S333–S333. 15 indexed citations
19.
Stock, Elyse, William H. Carson, Stephen Kaplita, et al.. (2003). Safety and tolerability meta-analysis of aripiprazole in schizophrenia. Schizophrenia Research. 60(1). 367–367. 4 indexed citations
20.
Marcus, R., et al.. (2002). Aripiprazole versus placebo in acute mania. European Neuropsychopharmacology. 12. 289–289. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R.N. Marcus Breakdown of academic impact, for papers by Baerbel Allingham Breakdown of academic impact, for papers by Na Jin Breakdown of academic impact, for papers by Sheila Assunção-Talbott Breakdown of academic impact, for papers by Angela Hill Breakdown of academic impact, for papers by Philippe Bouhours Breakdown of academic impact, for papers by Mary Mackle Breakdown of academic impact, for papers by Koen P. Grootens Breakdown of academic impact, for papers by W. Chrzanowski Breakdown of academic impact, for papers by Minna Torniainen
Rankless by CCL
2026